RG 6344
Alternative Names: RG-6344; RO-7276389Latest Information Update: 29 Dec 2021
At a glance
- Originator Roche
- Class Antineoplastics
- Mechanism of Action Proto-oncogene protein b-raf inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Malignant melanoma; Solid tumours
Most Recent Events
- 15 Dec 2021 Phase-I clinical trials in Malignant melanoma (Combination therapy, Late-stage disease, Metastatic disease) in New Zealand (PO) (ISRCTN13713551)
- 15 Dec 2021 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease) in New Zealand (PO) (ISRCTN13713551)
- 08 Dec 2021 Preclinical trials in Solid tumours (Metastatic disease, Late-stage disease) in Switzerland (PO) prior to December, 2021